Restless Legs SyndromeRLS-SleepNCT06889324
Efficacy of Vibration Therapy on Restless Legs Syndrome and Sleep Disturbances Among Patients Undergoing Hemodialysis
A study testing Vibration therapy in people with Restless Legs Syndrome, run by Amjed Abdulabbas Shraida at 1 site in Iraq.
Trial summary
The goal of this clinical trial is to learn if whether vibration therapy relieves the intensity of Restless legs syndrome (RLS) symptoms and sleep disturbances among patients undergoing hemodialysis. Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Restless Legs Syndrome
- What is being tested?
- Vibration therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteIraq
- Study dates
- 28 Jun 2025to 1 Sep 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients passing at least three months after first their hemodialysis
- Patients who are receiving two or more HD sessions a week, to facilitate patient follow-up.
- Patients who are willing to participate, because the patients' participation is voluntary.
- Patients who are alert and able to communicate verbally, to make the program applicable and facilitate the data collection.
Who cannot join
- Emergency hemodialysis patients, to avoid mal-efficient (apply the program in a harmless manner).
- Intake of drugs for restless leg syndrome and sleep disturbances.
- Using vibration and massage therapy at home
- Recent history of deep vein thrombosis or other vascular complications.
- Patients who are unable to communicate, because the patients' communication is an essential part of data collection.
- Patients with severe cardiovascular disorders such as unstable angina, recent myocardial infarction or severe heart failure, because the application of the program may increase cardiovascular stress, which may pose a risk to these patients.
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this clinical trial is to learn if whether vibration therapy relieves the intensity of Restless legs syndrome (RLS) symptoms and sleep disturbances among patients undergoing hemodialysis. The main question it aims to answer is:
Is there a difference in the levels of legs restless syndrome and sleep disturbances between hemodialysis patients who receive vibration therapy and those who do not receive it?
Read more
Researcher will compare the levels of legs restless syndrome and sleep disturbances between hemodialysis patients who receive vibration therapy and those who do not receive it to see if vibration therapy works to relieve the levels of legs restless syndrome and sleep disturbances.
Participants will take vibration therapy applied on the calf muscle for 10 minutes per session, 2 times per week for total one month, during the first hour of each hemodialysis sessions.
Read the detailed description
Background Most hemodialysis patients are faced with a variety of complications such as restless leg syndrome and sleep disorders during the course of their disease. Restless legs syndrome (RLS) is one of the most prevalent problems in patients receiving hemodialysis. Studies indicate that the prevalence of this sensorimotor neurological disorder in hemodialysis patients ranges from (6.6%) to (80%), contrasted to (7%) to (24.1%) in the general population. RLS adversely affects outcomes of patients with chronic renal failure receiving long-term hemodialysis, with significant impacts on sleep quality and quality of life, as well as increased mortality after 2.5 years of follow-up.
In terms of sleep, the quality of sleep in hemodialysis patients is often affected by restless legs syndrome. The individual feels very disturbing, deep creeping sensations inside the leg whenever sitting or lying down. These abnormal sensations cause insomnia, daytime sleepiness, shorter sleep duration, and the use of sedatives and hypnotics. Sleep disturbances and deprivation of sleep induced by RLS can impact the sleep quality and emotional well-being of patients undergoing hemodialysis, potentially resulting in depression, anxiety, and increment risk of cardiovascular issues.
Dialysis nurses should manage hemodialysis problems using efficient nonpharmacological techniques. As previously said, RLS significantly effects on both the physical and mental soundness of patients, in addition to disrupting their daily lives. Furthermore, many of the medications used to treat these individuals are mostly eliminated by the kidneys, producing further complications for the patients. These matters underscore the need of employing non-pharmacological approaches to treat restless legs syndrome and sleep disorders.
Importance of study There are approximately 3,730,000 patients with Chronic kidney Disease (CKD) globally, and the annual growth rate of the disease is 5-6%. According to data, more than 2.5 million patients with end-stage kidney disease are currently undergoing renal replacement therapy (RRT), and this figure is expected to rise to around 4.5 million by 2030. For patients with CKD, the most prevalent technique of RRT is hemodialysis.
Patients with kidney failure receiving continuous hemodialysis experience a variety of symptoms, including restless leg syndrome (RLS) and sleep disturbances. RLS is a clinical disorder with a prevalence ranging from 6.6% to 83% among patients receiving hemodialysis. It is characterized by a strong desire to move the legs, and this desire usually take place in the afternoon and evening. The moving desire is accompanied by uncomfortable and frequently painful feelings in the legs. The legs movement can help reduce painful and uncomfortable legs feelings. Above 90% of individuals with RLS have periodic leg movements (PLM) during sleeping. The periodic leg movements (PLMs) are sporadic and cause involuntary foot dorsiflexion, knee flexion, and sometimes thigh flexion, occurring every 20 to 40 seconds. The uncomfortable nighttime sensibility and need to move the legs generate intermittent movements of leg during sleep, which lateness and disrupt sleep, resulting in repeated awakenings, and promoting daytime drowsiness, all of which reduce the quality of life for patients.
Regarding sleep, Sleep disorders are common issues that many patients on hemodialysis experience. It is thought that these individuals have a prevalence of sleep problems that varies from 18% to 69% in different forms, such as patients with restless leg syndrome linked to obstructive sleep apnea. Sleep quality refers to an individual's contentment with their sleep experience, which encompasses many aspects like how quickly fall asleep, the total duration of sleep, the ability to stay asleep, and the feeling of being refreshed upon waking. Deprivation of sleep produces many issues like chronic weariness, malfunction, alterations in the neurological system, and decreased willingness to care for oneself, thus it is essential to focus on sleep quality and address sleep deprivation in patients undergoing hemodialysis.
Many pharmacological or non-pharmacological therapies can be used to treat patients with end-stage renal disease (ESKD) who have restless legs syndrome (RLS) and sleep disturbances. RLS treatments include dopamine agonists (pramipexole and ropinirole), antiepileptics (gabapentin), hypnotics, opiates (tramadol), and sedatives. Despite their effectiveness in alleviating symptoms and improving sleep time, these drugs have side effects such as headache, general weakness, nausea, emesis, and drowsiness, which eventually cause the symptoms of RLS to rebound and worsen. As for non-pharmacological approach, which include many interventions such as vibration, massage, exercise, aromatherapy, reflexology, cryotherapy, and cold dialysis, they have been reported to reduce the symptoms of restless legs syndrome in patients receiving hemodialysis. Unfortunately, these non-pharmacological approaches are offered in randomized studies that lack well-determined control groups, leading to a loss of clarity in the objective analysis of the study results. In addition, Salib and others encourage further studies involving a larger patient population and longer follow-up periods to identify the most suitable, safe, and cost-effective methods for managing this condition in hemodialysis patients. Conducting a study fills this gap by providing empirical data to support or refute the potential benefits of this intervention. This contributes to the evidence base in nephrology and rehabilitation medicine.
So the current study aims to find out whether vibration therapy relieves the intensity of RLS symptoms and sleep disturbances among patients undergoing hemodialysis. Exploring how vibration therapy affects symptoms like RLS and sleep disturbances can provide insights into the underlying mechanisms of these conditions in hemodialysis patients. As well as the positive findings from the study could potentially influence clinical practice guidelines for managing RLS and sleep disturbances in hemodialysis settings. Healthcare providers may consider integrating vibration therapy into multidisciplinary treatment plans to enhance symptom management and improve patient outcomes.
Research design:
In the current study, the researcher will utilize a pretest-posttest randomized controlled trial design.
Setting:
The study will be conducted in Al-Najaf City/Al-Najaf Al-Ashraf Health Directorate / Al-Sadder Medical City / The Specialized Center for Kidney Diseases and Transplantation / Hemodialysis Unit. This center was chosen due to the availability of patients, in addition to the fact that patients undergo dialysis treatment according to a specific schedule, which helps researcher to control the follow-up of patients.
Study samples:
Patients undergoing hemodialysis who have legs restless syndrome and sleep disturbances.
Sampling method :
According to Consolidated Standards of Reporting Trials (CONSORT), the patients undergoing hemodialysis will be assessed for eligibility to assign the sample for the study. The sample will then be allocated randomly into two groups; the study group and the control group, in this step a simple random sampling technique well be used to ensure that selection is unbiased and every individual has an equal chance of being chosen in order to achieve randomization when the sample is allocated into two groups.
Minimum sample size:
The sample size for the current study will be established using the G-Power analysis approach. The G-Power analysis method includes three parameters; power (minimum 80%), significance (0.05), and effect size. The researcher identified the following determinants to determine the sample size in the current study with a power greater than (95%): Significance (0.05), and effect size (0.5). So, the required sample size equals 70 (35 study group and 35 control group).
Data analysis:
The following statistical data analysis technique will be utilized to examine the study's data using the IBM Statistical Package for Social Science (SPSS) Ver. (19) and Microsoft Excel (2010):
- Descriptive Data Analysis:
- Tables (Frequencies, and Percentages).
- Statistical figures (Bar Charts).
- Statistical mean and standard deviation.
- Inferential Data Analysis:
- Paired sample t-test to identifying the mean difference between the pre-test and post-test for the control group.
- ANOVA: To compare the difference in the mean values of levels of legs restless syndrome and sleep disturbances among the participants of study group throughout three periods of measurements.
- Regression: to determine the relationship between socio-demographic data with Post-test 1 and Post-test 2 for the study group.
- Conditions
- Restless Legs Syndrome
- Being tested
- Vibration therapy
- Keywords
- Restless Legs Syndrome, Sleep disturbances, Hemodialysis
- Medical subject headings
- Restless Legs Syndrome, Parasomnias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vibration therapyOther
Its therapy uses mechanical vibrations delivered via a specialized device called Thrive vibrator device model 717 to stimulate the calf muscles, which can help reduce the severity of restless legs syndrome and sleep disturbances among patients undergoing hemodialysis.
| Study group | Role | What they receive |
|---|---|---|
| Vibration therapy | Experimental | Experimental group will take vibration therapy applied on the calf muscle for 10 minutes per session, 2 times per week for total one month, during the first hour of each hemodialysis sessions Receives: Other: Vibration therapy |
| Routine care | No intervention | Control group will not exposed to the vibration therapy and will take only routine care. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Arabic version of the Restless Legs Syndrome Rating Scale
A five-level Likert rating scale will be employed for rating the severity of Legs Restless Syndrome among patients receiving hemodialysis, ranging from (0 to 4) where (0) representing no RLS, (1) representing mild RLS, (2) representing moderate RLS, (3) representing severe RLS, and (4) represents very severe RLS. The scale consists of 10 items, and the maximum total score for the patient's answers is (40), higher scores indicate more severe symptoms. The severity of RLS is scored as (0) for no RLS, (1 - 10) for mild RLS, (11 - 20) for moderate RLS, (21 - 30) for severe RLS, and (31 - 40) for very severe RLS.
Measured: There will be three time points at which the measurement is assessed for both the study and the control group as follows: Pre-test: At the first day Post-test 1: two weeks later . Post-test 2: four weeks later.
Brief Pittsburgh Sleep Quality Index (B-PSQI)
Brief Pittsburgh Sleep Quality Index (B-PSQI) is a self-reported measure with six components. The items are classified and evaluated in five categories: sleep quality, nocturnal awakenings, sleep efficiency, sleep duration, and sleep latency. Each sleep component is coded using a Likert scale ranging from 0 to 3. The sum of the five components gives a total score between 0 and 15, with higher values indicating poorer sleep quality. Scores from 0 to 5 indicate acceptable sleep quality, whereas scores of 6 or higher indicate poor sleep quality.
Measured: There will be three time points at which the measurement is assessed for both the study and the control group as follows: Pre-test: At the first day Post-test 1: two weeks later . Post-test 2: four weeks later.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2025
- Study start28 Jun 2025
- Primary completion1 Aug 2025
- Study completion1 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Restless Legs SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients with legs restless syndrome and sleep disturbances during hemodialysis will be assessed for eligibility. After that, the researcher will use a simple random sampling technique by writing the names of the patients on slips of paper and placing them in a bowl, mixing them well, and then pulling them randomly to allocate them into two groups; half patients as a study group will take vibration therapy applied on the calf muscle for 10 minutes per session, 2 times per week for total one month, during the first hour of each hemodialysis sessions, and the other half patients will not exposed to the therapy and will take only routine care and considered as the control group.
- Masking
- None (open label)
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amjed Abdulabbas Shraida
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Amjed Abdulabbas Shraida, Kufa University
- Investigators
- Amjed A Shraida, PhD, Principal investigator, Kufa University-Faculty of Nursing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06889324
- Sponsor's protocol ID
- BaghdadU
- Acronym
- RLS-Sleep
- Status last verified
- Sep 2025
- First submitted
- 15 Mar 2025
- Last updated
- 4 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Vibration Therapy on Restless Legs Syndrome and Sleep Disturbances Among Patients Undergoing Hemodialysis
- ClinicalTrials.gov ID
- NCT06889324
- Acronym / sponsor ID
- RLS-Sleep / BaghdadU
- Conditions
- Restless Legs Syndrome
- Keywords
- Restless Legs Syndrome, Sleep disturbances, Hemodialysis
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Amjed Abdulabbas ShraidaUniversity, hospital or other
- Study start
- 28 Jun 2025 (actual)
- Primary completion
- 1 Aug 2025 (actual)
- Study completion
- 1 Sep 2025 (estimated)
- First posted
- 21 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if whether vibration therapy relieves the intensity of Restless legs syndrome (RLS) symptoms and sleep disturbances among patients undergoing hemodialysis. The main question it aims to answer is:
Is there a difference in the levels of legs restless syndrome and sleep disturbances between hemodialysis patients who receive vibration therapy and those who do not receive it?
Researcher will compare the levels of legs restless syndrome and sleep disturbances between hemodialysis patients who receive vibration therapy and those who do not receive it to see if vibration therapy works to relieve the levels of legs restless syndrome and sleep disturbances.
Participants will take vibration therapy applied on the calf muscle for 10 minutes per session, 2 times per week for total one month, during the first hour of each hemodialysis sessions.
Detailed description
Background Most hemodialysis patients are faced with a variety of complications such as restless leg syndrome and sleep disorders during the course of their disease. Restless legs syndrome (RLS) is one of the most prevalent problems in patients receiving hemodialysis. Studies indicate that the prevalence of this sensorimotor neurological disorder in hemodialysis patients ranges from (6.6%) to (80%), contrasted to (7%) to (24.1%) in the general population. RLS adversely affects outcomes of patients with chronic renal failure receiving long-term hemodialysis, with significant impacts on sleep quality and quality of life, as well as increased mortality after 2.5 years of follow-up.
In terms of sleep, the quality of sleep in hemodialysis patients is often affected by restless legs syndrome. The individual feels very disturbing, deep creeping sensations inside the leg whenever sitting or lying down. These abnormal sensations cause insomnia, daytime sleepiness, shorter sleep duration, and the use of sedatives and hypnotics. Sleep disturbances and deprivation of sleep induced by RLS can impact the sleep quality and emotional well-being of patients undergoing hemodialysis, potentially resulting in depression, anxiety, and increment risk of cardiovascular issues.
Dialysis nurses should manage hemodialysis problems using efficient nonpharmacological techniques. As previously said, RLS significantly effects on both the physical and mental soundness of patients, in addition to disrupting their daily lives. Furthermore, many of the medications used to treat these individuals are mostly eliminated by the kidneys, producing further complications for the patients. These matters underscore the need of employing non-pharmacological approaches to treat restless legs syndrome and sleep disorders.
Importance of study There are approximately 3,730,000 patients with Chronic kidney Disease (CKD) globally, and the annual growth rate of the disease is 5-6%. According to data, more than 2.5 million patients with end-stage kidney disease are currently undergoing renal replacement therapy (RRT), and this figure is expected to rise to around 4.5 million by 2030. For patients with CKD, the most prevalent technique of RRT is hemodialysis.
Patients with kidney failure receiving continuous hemodialysis experience a variety of symptoms, including restless leg syndrome (RLS) and sleep disturbances. RLS is a clinical disorder with a prevalence ranging from 6.6% to 83% among patients receiving hemodialysis. It is characterized by a strong desire to move the legs, and this desire usually take place in the afternoon and evening. The moving desire is accompanied by uncomfortable and frequently painful feelings in the legs. The legs movement can help reduce painful and uncomfortable legs feelings. Above 90% of individuals with RLS have periodic leg movements (PLM) during sleeping. The periodic leg movements (PLMs) are sporadic and cause involuntary foot dorsiflexion, knee flexion, and sometimes thigh flexion, occurring every 20 to 40 seconds. The uncomfortable nighttime sensibility and need to move the legs generate intermittent movements of leg during sleep, which lateness and disrupt sleep, resulting in repeated awakenings, and promoting daytime drowsiness, all of which reduce the quality of life for patients.
Regarding sleep, Sleep disorders are common issues that many patients on hemodialysis experience. It is thought that these individuals have a prevalence of sleep problems that varies from 18% to 69% in different forms, such as patients with restless leg syndrome linked to obstructive sleep apnea. Sleep quality refers to an individual's contentment with their sleep experience, which encompasses many aspects like how quickly fall asleep, the total duration of sleep, the ability to stay asleep, and the feeling of being refreshed upon waking. Deprivation of sleep produces many issues like chronic weariness, malfunction, alterations in the neurological system, and decreased willingness to care for oneself, thus it is essential to focus on sleep quality and address sleep deprivation in patients undergoing hemodialysis.
Many pharmacological or non-pharmacological therapies can be used to treat patients with end-stage renal disease (ESKD) who have restless legs syndrome (RLS) and sleep disturbances. RLS treatments include dopamine agonists (pramipexole and ropinirole), antiepileptics (gabapentin), hypnotics, opiates (tramadol), and sedatives. Despite their effectiveness in alleviating symptoms and improving sleep time, these drugs have side effects such as headache, general weakness, nausea, emesis, and drowsiness, which eventually cause the symptoms of RLS to rebound and worsen. As for non-pharmacological approach, which include many interventions such as vibration, massage, exercise, aromatherapy, reflexology, cryotherapy, and cold dialysis, they have been reported to reduce the symptoms of restless legs syndrome in patients receiving hemodialysis. Unfortunately, these non-pharmacological approaches are offered in randomized studies that lack well-determined control groups, leading to a loss of clarity in the objective analysis of the study results. In addition, Salib and others encourage further studies involving a larger patient population and longer follow-up periods to identify the most suitable, safe, and cost-effective methods for managing this condition in hemodialysis patients. Conducting a study fills this gap by providing empirical data to support or refute the potential benefits of this intervention. This contributes to the evidence base in nephrology and rehabilitation medicine.
So the current study aims to find out whether vibration therapy relieves the intensity of RLS symptoms and sleep disturbances among patients undergoing hemodialysis. Exploring how vibration therapy affects symptoms like RLS and sleep disturbances can provide insights into the underlying mechanisms of these conditions in hemodialysis patients. As well as the positive findings from the study could potentially influence clinical practice guidelines for managing RLS and sleep disturbances in hemodialysis settings. Healthcare providers may consider integrating vibration therapy into multidisciplinary treatment plans to enhance symptom management and improve patient outcomes.
Research design:
In the current study, the researcher will utilize a pretest-posttest randomized controlled trial design.
Setting:
The study will be conducted in Al-Najaf City/Al-Najaf Al-Ashraf Health Directorate / Al-Sadder Medical City / The Specialized Center for Kidney Diseases and Transplantation / Hemodialysis Unit. This center was chosen due to the availability of patients, in addition to the fact that patients undergo dialysis treatment according to a specific schedule, which helps researcher to control the follow-up of patients.
Study samples:
Patients undergoing hemodialysis who have legs restless syndrome and sleep disturbances.
Sampling method :
According to Consolidated Standards of Reporting Trials (CONSORT), the patients undergoing hemodialysis will be assessed for eligibility to assign the sample for the study. The sample will then be allocated randomly into two groups; the study group and the control group, in this step a simple random sampling technique well be used to ensure that selection is unbiased and every individual has an equal chance of being chosen in order to achieve randomization when the sample is allocated into two groups.
Minimum sample size:
The sample size for the current study will be established using the G-Power analysis approach. The G-Power analysis method includes three parameters; power (minimum 80%), significance (0.05), and effect size. The researcher identified the following determinants to determine the sample size in the current study with a power greater than (95%): Significance (0.05), and effect size (0.5). So, the required sample size equals 70 (35 study group and 35 control group).
Data analysis:
The following statistical data analysis technique will be utilized to examine the study's data using the IBM Statistical Package for Social Science (SPSS) Ver. (19) and Microsoft Excel (2010):
- Descriptive Data Analysis:
- Tables (Frequencies, and Percentages).
- Statistical figures (Bar Charts).
- Statistical mean and standard deviation.
- Inferential Data Analysis:
- Paired sample t-test to identifying the mean difference between the pre-test and post-test for the control group.
- ANOVA: To compare the difference in the mean values of levels of legs restless syndrome and sleep disturbances among the participants of study group throughout three periods of measurements.
- Regression: to determine the relationship between socio-demographic data with Post-test 1 and Post-test 2 for the study group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Patients with legs restless syndrome and sleep disturbances during hemodialysis will be assessed for eligibility. After that, the researcher will use a simple random sampling technique by writing the names of the patients on slips of paper and placing them in a bowl, mixing them well, and then pulling them randomly to allocate them into two groups; half patients as a study group will take vibration therapy applied on the calf muscle for 10 minutes per session, 2 times per week for total one month, during the first hour of each hemodialysis sessions, and the other half patients will not exposed to the therapy and will take only routine care and considered as the control group.
| Arm | Type | Receives |
|---|---|---|
| Vibration therapy | Experimental | Other: Vibration therapyExperimental group will take vibration therapy applied on the calf muscle for 10 minutes per session, 2 times per week for total one month, during the first hour of each hemodialysis sessions |
| Routine care | No intervention | –Control group will not exposed to the vibration therapy and will take only routine care. |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Patients passing at least three months after first their hemodialysis
- Patients who are receiving two or more HD sessions a week, to facilitate patient follow-up.
- Patients who are willing to participate, because the patients' participation is voluntary.
- Patients who are alert and able to communicate verbally, to make the program applicable and facilitate the data collection.
Key exclusion criteria (6 listed)
- Emergency hemodialysis patients, to avoid mal-efficient (apply the program in a harmless manner).
- Intake of drugs for restless leg syndrome and sleep disturbances.
- Using vibration and massage therapy at home
- Recent history of deep vein thrombosis or other vascular complications.
- Patients who are unable to communicate, because the patients' communication is an essential part of data collection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vibration therapyIts therapy uses mechanical vibrations delivered via a specialized device called Thrive vibrator device model 717 to stimulate the calf muscles, which can help reduce the severity of restless legs syndrome and sleep disturbances among patients undergoing hemodialysis. | Other | Vibration therapy |
Primary outcome
Arabic version of the Restless Legs Syndrome Rating Scale
Time frame: There will be three time points at which the measurement is assessed for both the study and the control group as follows: Pre-test: At the first day Post-test 1: two weeks later . Post-test 2: four weeks later.
A five-level Likert rating scale will be employed for rating the severity of Legs Restless Syndrome among patients receiving hemodialysis, ranging from (0 to 4) where (0) representing no RLS, (1) representing mild RLS, (2) representing moderate RLS, (3) representing severe RLS, and (4) represents very severe RLS. The scale consists of 10 items, and the maximum total score for the patient's answers is (40), higher scores indicate more severe symptoms. The severity of RLS is scored as (0) for no RLS, (1 - 10) for mild RLS, (11 - 20) for moderate RLS, (21 - 30) for severe RLS, and (31 - 40) for very severe RLS.
Brief Pittsburgh Sleep Quality Index (B-PSQI)
Time frame: There will be three time points at which the measurement is assessed for both the study and the control group as follows: Pre-test: At the first day Post-test 1: two weeks later . Post-test 2: four weeks later.
Brief Pittsburgh Sleep Quality Index (B-PSQI) is a self-reported measure with six components. The items are classified and evaluated in five categories: sleep quality, nocturnal awakenings, sleep efficiency, sleep duration, and sleep latency. Each sleep component is coded using a Likert scale ranging from 0 to 3. The sum of the five components gives a total score between 0 and 15, with higher values indicating poorer sleep quality. Scores from 0 to 5 indicate acceptable sleep quality, whereas scores of 6 or higher indicate poor sleep quality.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Restless Legs Syndrome
RecruitingObservational study
Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients
Chronic Insomnia, Chronic Pain
Not yet recruiting
Neuromodulation to Overcome Severe Restless Legs Syndrome
Restless Leg Syndrome (RLS), Spinal Cord Stimulation (SCS)
Not yet recruitingPhase 2
Tolerability and Efficacy of CBD Extract for RLS Treatment
Restless Leg Syndrome
Recruiting
Functional Connectivity of the Interoceptive Network in RLS
Restless Legs Syndrome
Not yet recruitingPhase 2
Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI
Restless Legs Syndrome (RLS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Amjed A Shraida, PhD principal investigator
Kufa University-Faculty of Nursing
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vibration therapy in people with Restless Legs Syndrome, run by Amjed Abdulabbas Shraida at 1 site in Iraq.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Arabic version of the Restless Legs Syndrome Rating Scale (time frame: There will be three time points at which the measurement is assessed for both the study and the control group as follows: Pre-test: At the first day Post-test 1: two weeks later . Post-test 2: four weeks later.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.